This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
Five-year follow-up overall survival data from the X-ACT (Xeloda in Adjuvant Colon Cancer Trial) study show that oral chemotherapy Xeloda (R) (capecitabine) is as effective as the current standard treatment - intravenous bolus 5- FU/LV (5-fluorouracil leucovorin) - in the adjuvant treatment of Dukes' C colon cancer. These data were presented today at the 14th European Cancer Conference (ECCO) in Barcelona, Spain.
We care about your feedback. Let us know how we can improve your CancerCompass experience.